Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- New trial
Lymphoma
Phase 1 huCART19-IL18-eDHFR CD19 CAR-T secreting IL-18 with PET cell-tracking
This Phase 1, open-label, single-arm study from the University of Pennsylvania tests huCART19-IL18-eDHFR: an autologous, CD19-directed CAR T-cell therapy “armored” to secrete interleukin‑18 (IL‑18) to boost antitumor…
NCT07343934 First-in-human - New trial Spotlight
Multiple myeloma
Phase 3 JNJ-79635322 BCMA/GPRC5D×CD3 trispecific antibody vs teclistamab BCMA×CD3 bispecific in RRMM
Janssen Research & Development (Johnson & Johnson) is running this Phase 3 randomized head-to-head study (TRIlogy-5) to compare JNJ-79635322 versus teclistamab in relapsed/refractory multiple myeloma after 1–3 prior…
NCT07518186 Registrational - New trial
Multiple myeloma
Phase 3 isatuximab (anti-CD38 mAb) + iberdomide (CRBN E3 ligase modulator) in transplant-eligible NDMM
Dana-Farber Cancer Institute’s randomized DETERMINATION 2 program tests whether a risk- and MRD/response-adapted strategy can improve outcomes for newly diagnosed, transplant-eligible multiple myeloma. Everyone…
NCT07624513 Exploratory - New trial
Multiple myeloma
Phase 3 cevostamab FCRH5×CD3 bispecific antibody plus Pd in relapsed multiple myeloma
Hoffmann‑La Roche/Genentech’s CEVOLUTION (Phase 3) is a randomized, open-label, multicenter study testing cevostamab + pomalidomide + dexamethasone (CevosPd) versus investigator’s choice standard regimens in…
NCT07555938 Registrational - New trial Spotlight
Chronic lymphocytic leukemia
Phase 3 sonrotoclax (BGB-11417) BCL2 inhibitor plus zanubrutinib BTK inhibitor in untreated CLL
BeOne Medicines’ Phase 3 open-label, randomized study (BGB-11417-304; CELESTIAL‑TNCLL‑2) tests whether fixed-duration sonrotoclax + zanubrutinib can improve outcomes versus a fixed-duration control of venetoclax +…
NCT07277231 Registrational - New trial Spotlight
Pancreatic cancer
Phase 3 zoldonrasib (RMC-9805) KRAS G12D-selective RAS(ON) inhibitor plus chemo in 1L metastatic PDAC.
This registrational, randomized, double-blind, placebo-controlled Phase 3 study (RASolute 305) tests whether adding zoldonrasib (RMC-9805)—Revolution Medicines’ oral KRAS G12D-selective “RAS(ON)” inhibitor that…
NCT07621718 Registrational - New trial
Pancreatic cancer
Early-feasibility Aliya PEF system irreversible electroporation (non-thermal membrane disruption) in pancreatic tumors.
This early feasibility, single-arm interventional study at The Ohio State University Comprehensive Cancer Center evaluates whether endoscopic ultrasound (EUS)-guided pulsed electric field (PEF) ablation can be…
NCT07619417 Exploratory - New trial
Pancreatic cancer
Phase 1/1b AB801 AXL receptor tyrosine kinase inhibitor with chemo + PD-(L)1 blockade
This Phase 1/1b, open-label, multi-cohort study evaluates AB801—an oral small-molecule AXL receptor tyrosine kinase inhibitor from Arcus Biosciences—combined with standard chemotherapy and immune checkpoint blockade…
NCT07619313 Exploratory - New trial
Ovarian cancer
Phase 2 mirvetuximab soravtansine FRα-targeted ADC (DM4 tubulin inhibitor) dose-optimizes combos in ovarian cancer.
AbbVie is running this Phase 2, open-label, randomized master protocol (M25-709; sometimes listed as FLORENZA/GOG-3126) to optimize mirvetuximab soravtansine (MIRV), a folate receptor alpha (FOLR1/FRα)–directed…
NCT07059845 Exploratory - New trial
Ovarian cancer
Phase 1/2 mocertatug rezetecan B7-H4–targeted topoisomerase I ADC combinations in gynecologic tumors.
GlaxoSmithKline’s BEHOLD-2 is a Phase 1/2 randomized, multi-cohort combination study testing mocertatug rezetecan (Mo‑Rez; a B7‑H4–directed antibody-drug conjugate delivering an exatecan-derived topoisomerase I…
NCT06796907 Exploratory - New trial
Head and neck cancer
Phase 1 camonsertib (ATR kinase inhibitor) plus SBRT re-irradiation in recurrent HNSCC
This Phase 1 NCI-sponsored study tests safety, tolerability, and the recommended Phase 2 dose of camonsertib—Repare Therapeutics’ oral ATR (ataxia telangiectasia and Rad3-related) kinase inhibitor—given concurrently…
NCT07156227 Exploratory - New trial
Stomach and esophageal cancer
Phase 2 cadonilimab PD-1×CTLA-4 bispecific antibody plus FLOT in resectable gastric/GEJ cancer
This Memorial Sloan Kettering–sponsored Phase 2, single-arm perioperative study tests whether adding cadonilimab to FLOT can safely deepen pathologic responses in locally advanced, resectable, HER2-negative gastric…
NCT07631000 Exploratory - New trial Spotlight
Multiple solid tumors
Phase 1/2 BLU-924 (SAR449336) pan-KRAS inhibitor in KRAS-mutant PDAC/NSCLC/CRC
This first-in-human, open-label Phase 1/2 trial tests BLU-924 (SAR449336), an oral pan-KRAS small-molecule inhibitor, as monotherapy and in combination therapy in people with metastatic, KRAS-mutant pancreatic ductal…
NCT07629960 First-in-human - New trial
Multiple solid tumors
Phase 2 TIMED trial tests PD‑1/PD‑L1 checkpoint blockade timing (morning vs afternoon).
UNC Lineberger Comprehensive Cancer Center is running this Phase 2, open-label, randomized, parallel-assignment study to test whether *time of day* changes outcomes from standard immune checkpoint inhibitors in solid…
NCT07630168 Exploratory - New trial
Multiple solid tumors
Phase 1/2 ALK201 FGFR2b-targeting ADC (TOP1 inhibitor payload) in advanced solid tumors
This first-in-human, open-label Phase 1/2 trial evaluates ALK201 monotherapy in adults with advanced/metastatic solid tumors, using sequential dose escalation (to define dose-limiting toxicities, maximum tolerated…
NCT06656390 First-in-human - New trial
Multiple solid tumors
Phase 1 GSK5533524 antibody–drug conjugate (ADC) targeting an undisclosed tumor-associated antigen
No disclosed MOA. We do not include details of trials without this basic information.
NCT07438782 First-in-human - Trial result Spotlight
Non-small cell lung cancer
Sevabertinib (HER2 TKI) sustains 67–75% ORR in HER2-mutant NSCLC with no ILD signal
Sevabertinib is a potent, reversible, oral HER2 (ERBB2) tyrosine kinase inhibitor evaluated at 20mg BID in the open-label Phase I/II SOHO-01 trial (NCT05099172) in advanced HER2–tyrosine kinase domain–mutant NSCLC…
NCT05099172 - Trial result Spotlight
Non-small cell lung cancer
Neladalkib (next-gen ALK TKI; TRK-sparing) posts 31% ORR post–multiple ALK TKIs, with 68% ORR in G1202R ALK+ NSCLC
Neladalkib is an investigational, brain-penetrant ALK tyrosine kinase inhibitor designed to cover single/compound ALK resistance mutations (including G1202R) while sparing TRK, evaluated in the global single-arm…
NCT05384626 - Trial result Spotlight
Non-small cell lung cancer
Lunbotinib (A400/EP0031) selective RET inhibitor posts 81–87% ORR and 27.5-mo mPFS in RET-fusion NSCLC
Lunbotinib is an oral, brain-penetrant next-generation selective RET inhibitor designed to inhibit RET fusion and mutant proteins, evaluated in a pivotal Phase II, two-cohort, single-arm study in China (NCT05265091)…
NCT05265091 - Trial result Spotlight
Non-small cell lung cancer
Divarasib (KRAS G12C inhibitor) + pembrolizumab drives 73% ORR and 19.3-mo PFS in 1L KRAS G12C+ NSCLC
Divarasib is an oral, next-generation covalent KRAS G12C inhibitor combined with pembrolizumab (PD-1) in the open-label Phase Ib/II Krascendo-170 dose-finding/expansion study (NCT05789082) in untreated…
NCT05789082 - Trial result Spotlight
Non-small cell lung cancer
BH-30643 (OMNI‑EGFR mutant‑selective macrocyclic TKI) shows 59% ORR in post‑osimertinib C797S NSCLC (incl CNS)
BH-30643 is a first-in-class macrocyclic, non-covalent “OMNI‑EGFR” inhibitor engineered to selectively hit EGFR driver mutations while largely sparing WT EGFR and retaining activity against C797S with or without…
NCT06706076 - Trial result Spotlight
Non-small cell lung cancer
SSGJ-707 (PF-08634404) PD-1×VEGF Bispecific Delivers 67.6% ORR and 12.4-mo mPFS in 1L PD-L1+ NSCLC
SSGJ-707 is a fully human IgG4 bispecific antibody that simultaneously binds PD-1 and VEGF, aiming to pair checkpoint blockade with anti-angiogenic activity in a single agent. In the Phase 2 NCT06361927 dose-finding…
NCT06361927 - Trial result Spotlight
Non-small cell lung cancer
Lattice SF-SBRT + Toripalimab/Chemo Drives 95% MPR in Resectable NSCLC
Lattice spatially fractionated SBRT delivers a single preoperative radiation fraction with a 12 Gy peak and <4 Gy valley, here combined with toripalimab, a PD-1 antibody, plus platinum-doublet chemotherapy in a…
NCT06293690 - Trial result
Non-small cell lung cancer
FLARE-RT PET/SPECT-guided risk-adaptive RT boosts durability of locoregional control in unresectable NSCLC
FLARE-RT (Phase II; NCT02773238) tested biological image-guided chemoradiation for AJCCv7 stage IIB–IIIB unresectable NSCLC (n=49), combining functional lung avoidance (SPECT/CT) with mid-treatment FDG-PET response…
NCT02773238 - Trial result
Non-small cell lung cancer
Pembrolizumab (PD-1) + platinum doublet chemo shows larger OS benefit after crossover adjustment in 1L metastatic NSCLC
Pembrolizumab is an anti–PD-1 monoclonal antibody; here, pooled 5-year follow-up datasets from Phase 3 KEYNOTE-189 (nonsquamous; n=646 across global + Japan extension) and KEYNOTE-407 (squamous; n=669 across global +…
- Trial result
Non-small cell lung cancer
Nivolumab (PD-1) adjuvant therapy fails to extend DFS after NSCLC resection + chemo (EA5142/ALCHEMIST)
Nivolumab is an anti–PD-1 checkpoint inhibitor tested as 1 year of adjuvant therapy (480 mg IV q4w) after surgery and completion of standard adjuvant chemotherapy and/or PORT in resected high-risk NSCLC (tumor ≥4cm…
NCT02595944 - Trial result
Non-small cell lung cancer
Adjuvant erlotinib (EGFR TKI) fails to improve OS after resection in EGFR-mutant NSCLC
Erlotinib is a first-generation oral EGFR tyrosine kinase inhibitor (exon19 del/L858R) tested in the ALCHEMIST/Alliance A081105 randomized Phase 3 adjuvant trial (NCT02193282) in completely resected stage IB (≥4cm),…
NCT02193282 - Trial result
Non-small cell lung cancer
Pembrolizumab + lenvatinib (VEGFR/FGFR TKI) hits biomarker-gated ORR in 1L NSCLC, but survival looks broadly similar across groups
Pembrolizumab (anti–PD-1) was combined with lenvatinib (multi-kinase VEGFR/FGFR inhibitor), quavonlimab (CTLA-4 mAb), or favezelimab (LAG-3 mAb) in the biomarker-directed, adaptively randomized Phase 2…
NCT03516981 - Trial result
Non-small cell lung cancer
Nogapendekin alfa inbakicept (NAI; IL-15R agonist) boosts PFS/OS signals when added to 1L PD-1–based SOC in metastatic NSCLC
Nogapendekin alfa inbakicept (NAI) is an IL-15 receptor agonist designed to expand NK cells and effector/memory T cells and sustain absolute lymphocyte counts (ALC), aiming to preserve “immune competence” during…
NCT03520686 - Trial result
Non-small cell lung cancer
Durvalumab (anti–PD-L1) reshapes the TME and deepens EFS benefit in resectable NSCLC (AEGEAN)
Durvalumab is a PD-L1–blocking antibody given perioperatively with platinum-based neoadjuvant chemotherapy (4 cycles Q3W) then adjuvantly (12 cycles Q4W) in the Phase 3, double-blind AEGEAN trial (NCT03800134) in…
NCT03800134
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.